Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma

  • Authors:
    • Yingbin Lao
    • Huazhang Wu
    • Chengchegn Zhao
    • Qunying Wu
    • Fengchang Qiao
    • Hong Fan
  • View Affiliations

  • Published online on: July 19, 2013     https://doi.org/10.3892/br.2013.142
  • Pages: 771-775
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is one of the most common solid tumors worldwide. Epigenetic changes in gene expression, including DNA methylation and histone modifications, may contribute to the development of HCC. Polymorphisms of the DNA methyltransferase 3B (DNMT3B) gene may affect the activity of this enzyme and increase the susceptibility to several types of cancer, including HCC. To confirm this hypothesis, we investigated the association between single‑nucleotide polymorphisms‑149C>T (rs2424913) and ‑579G>T (rs1569686) in the promoter region of DNMT3B and the risk of HCC. DNMT single‑nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction‑restriction fragment length polymorphism in 108 HCC patients and 240 healthy controls matched for age, gender and ethnicity. The DNMT3B‑149 TT genotype was not significantly asso­ciated with an increased risk of HCC. The frequency of DNMT3B‑149C was 0.46% in HCC patients and 1.39% in healthy individuals, whereas the frequency of DNMT3B‑579G was 8.33% in HCC patients and 10.42% in healthy individuals. No significant differences were observed in the genotype or allelic distribution between HCC patients and controls. In conclusion, DNMT3B‑149C>T and ‑579G>T polymorphisms are not significantly associated with an increased risk of HCC. these results demonstrated that these particular SNPs may not be used as biomarkers to predict susceptibility to HCC.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, the third leading cause of cancer-related mortality worldwide and the second leading cause of cancer-related mortality in China (1,2). The cause of HCC is a complex interplay between numerous factors (3). Accumulating evidence in molecular genetics indicate that single-nucleotide polymorphisms (SNPs) in immune response-, angiogenesis- and tumorigenesis-related genes are associated with susceptibility to HCC (47). Recent advances in genome-wide association studies also identified new susceptibility loci for HCC (8,9), which may help elucidate the underlying mechanism of genetic variations in the development of HCC.

Recent investigations on gene methylation utilizing genome- wide techniques revealed that a large number of genes exhibit aberrant DNA methylation profiles in cancer (10). These changes may be used to stratify cancer subtypes and predict cancer outcomes (11,12). DNA methyltransferase 3B (DNMT3B) plays a crucial role in embryonic development and aberrant DNA methylation in carcinogenesis. Polymorphisms of the DNMT3B gene may regulate gene expression, affect enzymatic activity and contribute to the susceptibility to cancer. It was previously demonstrated that certain SNPs in the DNMT3B gene may affect DNMT3B activity on DNA methylation, thereby modulating the susceptibility to cancer (13). The DNMT3B-149C>T polymorphism confers a 30% increase in promoter activity in vitro(14,15). DNMT3B promoter polymorphisms were previously reported to be associated with the risk of lung, colorectal and head and neck cancer (14,16). Based on the evidence mentioned above, we used a candidate gene strategy and screened variations in the DNMT3B gene to investigate the association between these variations and HCC susceptibility in a Chinese population.

Materials and methods

Subjects

The patients and control subjects in this study were recruited between September, 2006 and June, 2008 from the Jiangsu Tumor Hospital in the Jiangsu province. Cases and controls were matched by age and gender. The characteristics of the cases and controls are presented in detail in Table I A and B. Samples were obtained following written consent and analyzed anonymously. This study was performed with the approval of the Medical Ethics Committee of the Medical School of Southeast University.

Table I

Characteristics of the study population.

Table I

Characteristics of the study population.

A, DNMT3B-149C>T

VariablesHCC cases (%) (n=108)Controls (%) (n=216)P-value
Age (years)
 <5035 (32.41)56 (25.93)0.221
 ≥5073 (67.59)160 (74.07)
Gender
 Male85 (78.70)152 (70.37)0.111
 Female23 (21.3)64 (29.63)

B, DNMT3B-579G>T

VariablesHCC cases (%) (n=114)Controls (%) (n=240)P-value

Age (years)
 <6062 (54.39)122 (50.83)0.532
 ≥6052 (45.61)118 (49.17)
Gender
 Male90 (78.95)170 (70.83)0.106
 Female24 (21.05)70 (29.17)

[i] DNMT3B, DNA methyltransferase 3B; HCC, hepatocellular carcinoma.

DNA extraction

Venous blood samples (5 ml) were collected from HCC patients and healthy control subjects in EDTA vacuum tubes. Genomic DNA was extracted from white blood cells within 1 week after sample collection by proteinase K digestion, as previously described (17).

DNMT3B SNP genotyping

The DNMT3B-149C>T and -579G>T SNPs were analyzed by polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLPs). The PCR was performed in a 25-μl volume containing 100 ng genomic DNA, 2.5 μl 10X PCR buffer, 2.0 mM MgCl2, 0.1 mM dNTPs (mixture of dATP, dTTP, dCTP and dGTP), 10 pmol of each primer (DNMT3B-149C>T primer: forward 5′-TGCTGTGACAGGCAGAGCAG-3′ and reverse 5′-GGT AGCCGGGAACTCCACGG-3′; DNMT3B-579G>T primer: forward 5′-GAGGTCTCATTATGCCTAGG-3′ and reverse 5′-GGGAGCTCACCTTCTAGAAA-3′), 1 unit of Taq DNA polymerase (Biocolor BioScience and Technology Co., Shanghai, China). The PCR cycle conditions consisted of an initial denaturation step at 95°C for 5 min, followed by 30 cycles at 95°C for 30 sec, at 62°C for 30 sec (−149C>T) or at 57°C for 30 sec (−579 G>T) and at 72°C for 30 sec, with a final elongation step at 72°C for 5 min. The 380-bp (DNMT3B-149C>T) fragment was digested with BlnI for 5 min at 37°C, the digested products were separated on 2.0% agarose gel and the PCR-RFLP bands were visualized under UV light with ethidium bromide staining. The T allele has a BlnI restriction site that resulted in two bands (207- and 173-bp) in the homozygous genotype, the heterozygote exhibited three bands (380-, 207- and 173-bp), whereas the variant C allele produced only one band representing the entire 380-bp fragment. The -579G>T polymorphism was determined by PCR-RFLPs. PvuII was used to detect the G-T transition. The DNMT3B T/T genotype was expected to exhibit two DNA bands at the positions of 132 and 93 bp, whereas the G/G genotype was expected to exhibit a single band (at 225 bp) and the heterozygote was expected to exhibit 3 bands (at 225, 132 and 93 bp). PCR was conducted and the results were evaluated without knowledge of the case-control status. The samples were successfully genotyped. For genotyping quality control, 5% of the samples were randomly selected and directly sequenced to obtain 100% identical results.

Statistical analysis

Data were analyzed with SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA). Patients and controls were compared using the Student’s t-test for continuous variables and the Chi-square (χ2) test for categorical variables. Allele and genotype frequencies between control subjects and HCC patients were obtained using the Chi-square test and the standard goodness-of-fit test was used to assess the Hardy-Weinberg equilibrium. P<0.05 was considered to indicate a statistically significant difference.

Results

The demographics of the cases and controls enrolled in this study are provided in Tables I A and B. No significant differences were observed in age and gender distribution between cases and controls, suggesting that the matching based on these two variables was adequate. There was no evidence of deviation from the Hardy-Weinberg equilibrium among the cases or controls. The genotypic and allelic frequencies of DNMT3B-149C>T are provided in Table II A. No significant differences were found in the genotypic and allelic frequencies between the two groups. Subsequently, we stratified the HCC cases by age and gender and no significantly different frequencies of -149C>T were observed (Table II B).

Table II

DNMT3B-149C>T genotype and allele frequency and distribution.

Table II

DNMT3B-149C>T genotype and allele frequency and distribution.

A, DNMT3B-149C>T genotype and allele frequency among cases and controls

HCC (n=108)Control subjects (n=216)


Genotype/alleleNo.(%)No.(%)Crude OR (95% CI)P-valuea
Genotype
 TT10799.0721097.221
 CT10.9362.780.327 (0.039–2.752)0.499b
 CC0c0.0000.00-
Allele
 C10.4661.391
 T21599.5442698.613.028 (0.362–25.313)0.502d

B, Distribution of-149C>T DNMT3B genotypes and association with age and gender in HCC cases

GenotypeAllele


GroupsCC (%)CT (%)TT (%)T (%)P-valuee

Age (years)0 (0.00)1 (0.93)107 (99.07)99.07
 <500 (0.00)0 (0.00)35 (32.40)100.001.000f
 ≥500 (0.00)1 (10.93)72 (66.67)98.63
Gender
 Male0 (0.00)0 (0.00)85 (78.70)100.000.213g
 Female0 (0.00)1 (0.93)22 (20.37)95.65

a Chi-square (χ2) test;

b HCC cases vs. controls;

c CC genotype not detected in HCC patients and control subjects;

d T allele vs. C allele;

e Chi-square (χ2) test;

f frequency of the T allele in individuals aged <50 vs. ≥50 years;

g frequency of the T allele in male vs. female individuals.

{ label (or @symbol) needed for fn[@id='tfn9-br-01-05-0771'] } DNMT3B, DNA methyltransferase 3B; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval.

As regards DNMT3B-579G>T, the distributions of the polymorphism genotypes among the HCC cases (TT, 83.33%; GT, 16.67%; and GG, 0%) exhibited no significant differences from those among the controls (TT, 80.83%; GT, 17.50%; and GG, 1.67%; P>0.05). No significant differences in allelic frequencies were observed between the two groups (Table III A). The stratified analysis revealed no significant difference in the distribution of the -579G>T genotype according to age or gender in the HCC patients (Table III B).

Table III

DNMT3B-579G>T genotype and allele frequency and distribution.

Table III

DNMT3B-579G>T genotype and allele frequency and distribution.

A, DNMT3B-579G>T genotype and allele frequency among cases and controls

HCC (n=114)Control subjects (n=240)


Genotype/alleleNo.(%)No.(%)Crude OR (95% CI)P-valuea
Genotype
 GT (ref.)1916.674217.501
 TT9583.3319480.831.082 (0.597–1.962)0.794b
 GG0c-41.671.452 (1.227–1.719)0.448
Allele
 G198.335010.421.000
 T20991.6743089.581.279 (0.735–2.225)0.382d

B, Distribution of DNMT3B-579G>T genotypes and allele frequencies among HCC cases and association with age and gender

GenotypeAllele


GroupsGG (%)GT (%)TT (%)T (%)P-valuee

Total0 (0.00)19 (16.67)95 (83.33)91.67
Age(years)
 <500 (0.00)12 (10.53)50 (43.86)90.320.423f
 ≥500 (0.00)7 (6.14)45 (39.47)93.27
Gender
 Male0 (0.00)14 (12.28)76 (66.67)92.220.919g
 Female0 (0.00)5 (4.39)19 (16.67)89.58

a Chi-square (χ2) test;

b HCC cases vs. controls;

c GG genotype not detected in HCC patients;

d G allele vs. T allele;

e Chi-square (χ2) test;

f frequency of the T allele among individuals aged <50 vs. ≥50 years;

g frequency of the T allele in male vs. female individuals.

{ label (or @symbol) needed for fn[@id='tfn17-br-01-05-0771'] } DNMT3B, DNA methyltransferase 3B; HCC, hepatocellular carcinoma; OR, odds ratio; CI, confidence interval.

Discussion

HCC is one of the most common malignant tumors, has a poor survival rate and is particularly prevalent in China, as well as in the rest of Asia. The identification of biomarkers for the early diagnosis and accurate prognosis of HCC is crucial for improving patient survival. Numerous tissue and serum markers associated with invasiveness, metastasis, recurrence and potential prognostic significance have been identified in HCC thus far (18,19).

In mammals, DNMT3B plays an important role in carcinogenesis and DNMT SNPs are important indicators of the genetic susceptibility to cancer development. Therefore, genetic polymorphism assays have been used to investigate the aetiology of malignant diseases (20). The significance of DNMT3B promoter genetic polymorphisms for tumorigenesis has been extensively investigated, although no consensus was reached due to the differences in tumors, ethnic groups, geographical areas or sample size between individual studies. A meta-analysis demonstrated that the -149C>T polymorphism of DNMT3B was not associated with colorectal cancer risk (21). It has also been demonstrated that the -579G>T SNP of the DNMT3B promoter decreased the susceptibility to lung and colon cancer (22,23), suggesting that the DNMT3B promoter -579G>T polymorphism may be used as a genetic risk factor to evaluate the population susceptible to tumor development. Khorshied and El-Ghamrawy (24) and Zhao et al(25) demonstrated that the DNMT3B -579G>T polymorphism represents a novel genetic risk factor for idiopathic thrombocytopenic purpura. However, it was also reported that there is no association between the -579G>T polymorphism and head and neck squamous cell carcinoma or esophageal carcinoma (26,27). A meta-analysis for -149C>T and -579G>T suggested that there was no evidence that individuals carrying the variant genotypes (CC+CT) have an increased risk of cancer compared to those carrying the wild homozygote TT genotype, although -579G>T was associated with a significantly decreased risk of cancer (28).

However, little is known about the association between the polymorphisms of the DNMT3B promoter and HCC. Therefore, we conducted a case-control study to investigate the association of the DNMT3B promoter -149C>T and -579G>T polymorphisms with genetic susceptibility to HCC and evaluate whether these SNPs may act as biomarkers to predict the susceptibility to HCC in a Chinese population. Wu and Lin (29) reported that DNMT3B-149C>T polymorphism was not associated with an increased risk of HCC in a Chinese population and Ezzikouri et al(30) demonstrated that the DNMT3B-149C>T genotype was not significantly associated with an increased risk of HCC in a Moroccan population. Our results are consistent with those of Wu and Lin (29) and Ezzikouri et al(30), with insignificant differences in genotype and allele frequency distribution between HCC patients and control subjects suggesting that these two particular SNPs are not associated with the risk of HCC in the study population.

To the best of our knowledge, this is the first study to investigate the association of DNMT3B-149C>T and -579G>T polymorphisms with genetic susceptibility to HCC. Our results suggest that the -149C>T and -579G>T polymorphisms do not affect the risk for HCC, at least in the Chinese population. This finding may provide valuable insight into hepatocellular carcinogenesis. However, a larger population has to be investigated and evaluated to elucidate the contribution of DNMT3B SNPs to the susceptibility to HCC in Chinese individuals. Furthermore, to elucidate the true effects of DNMT3B polymorphisms on determining the pathogenesis of HCC, investigations of other variants of DNMT3B (including promoter and coding regions) and their effects on the biological functions of DNMTs are also required.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81171915) and the QingLan Project of Jiangsu Province.

Abbreviations:

PCR

polymerase chain reaction

RFLP

restriction fragment length polymorphism

OR

odds ratio

CI

confidence interval

HCC

hepatocellular carcinoma

SNP

single-nucleotide polymorphism

References

1 

Wang Z, Cao Y, Jiang C, et al: Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS One. 7:e400392012. View Article : Google Scholar : PubMed/NCBI

2 

Thomas MB, Jaffe D, Choti MM, et al: Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 28:3994–4005. 2010. View Article : Google Scholar

3 

Chen CJ and Chen DS: Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology. 36:1046–1049. 2002. View Article : Google Scholar

4 

Kong SY, Park JW, Lee JA, et al: Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology. 46:446–455. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Deng G, Zhou G, Zhang R, et al: Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology. 134:716–726. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Clifford RJ, Zhang J, Meerzaman DM, et al: Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology. 52:2034–2043. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Long XD, Ma Y, Zhou YF, et al: Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population. Hepatology. 52:1301–1309. 2010. View Article : Google Scholar

8 

Kumar V, Kato N, Urabe Y, et al: Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 43:455–458. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Zhang H, Zhai Y, Hu Z, et al: Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet. 42:755–758. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Figueroa ME, Lugthart S, Li Y, et al: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 17:13–27. 2010. View Article : Google Scholar

11 

Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 17:510–522. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Portela A and Esteller M: Epigenetic modifications and human disease. Nat Biotechnol. 28:1057–1068. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar

14 

Shen H, Wang L, Spitz MR, et al: A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 62:4992–4995. 2002.PubMed/NCBI

15 

Wang L, Rodriguez M, Kim ES, et al: A novel C/T polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer. Int J Oncol. 25:993–999. 2004.PubMed/NCBI

16 

Taberlay PC and Jones PA: DNA methylation and cancer. Prog Drug Res. 67:1–23. 2011.

17 

Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:12151988. View Article : Google Scholar : PubMed/NCBI

18 

Paz MF, Fraga MF, Avila S, et al: A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63:1114–1121. 2003.PubMed/NCBI

19 

Egger G, Liang G, Aparicio A, et al: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Wjst M: Target SNP selection in complex disease association studies. BMC Bioinformatics. 5:922004. View Article : Google Scholar : PubMed/NCBI

21 

Fang C, Sun W, Han H, et al: The -149C>T polymorphism of DNMT3B is not associated with colorectal cancer risk: Evidence from a meta-analysis based on case-control studies. Exp Ther Med. 4:728–732. 2012.

22 

Lee SJ, Jeon HS, Jang JS, et al: DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis. 26:403–409. 2005.PubMed/NCBI

23 

Hong YS, Lee HJ, You CH, et al: DNMT3b 39179GT polymorphism and the risk of adenocarcinoma of the colon in Koreans. Biochem Genet. 45:155–163. 2007. View Article : Google Scholar : PubMed/NCBI

24 

Khorshied MM and El-Ghamrawy MK: DNA methyltransferase 3B (DNMT3B -579G>T) promotor polymorphism and the susceptibility to pediatric immune thrombocytopenic purpura in Egypt. Gene. 511:34–37. 2012.

25 

Zhao H, Du W, Gu D, et al: DNMT3B 579G>T promoter polymorphism and the risk for idiopathic thrombocytopenic purpura in a Chinese population. Acta Haematol. 122:31–35. 2009.

26 

Chang KP, Hao SP, Liu CT, et al: Promoter polymorphisms of DNMT3B and the risk of head and neck squamous cell carcinoma in Taiwan: a case-control study. Oral Oncol. 43:345–351. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Fan H, Liu DS, Zhang SH, et al: DNMT3B 579 G>T promoter polymorphism and risk of esophagus carcinoma in Chinese. World J Gastroenterol. 14:2230–2234. 2008.

28 

Zhu S, Zhang H, Tang Y, et al: DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case-control studies. Mol Biol Rep. 39:4429–4437. 2012. View Article : Google Scholar : PubMed/NCBI

29 

Wu Y and Lin JS: DNA methyltransferase 3B promoter polymorphism and its susceptibility to primary hepatocellular carcinoma in the Chinese Han nationality population: a case-control study. World J Gastroenterol. 13:6082–6086. 2007. View Article : Google Scholar

30 

Ezzikouri S, El Feydi AE, Benazzouz M, et al: Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol. 9:877–881. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September-October 2013
Volume 1 Issue 5

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lao Y, Wu H, Zhao C, Wu Q, Qiao F and Fan H: Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma. Biomed Rep 1: 771-775, 2013.
APA
Lao, Y., Wu, H., Zhao, C., Wu, Q., Qiao, F., & Fan, H. (2013). Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma. Biomedical Reports, 1, 771-775. https://doi.org/10.3892/br.2013.142
MLA
Lao, Y., Wu, H., Zhao, C., Wu, Q., Qiao, F., Fan, H."Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma". Biomedical Reports 1.5 (2013): 771-775.
Chicago
Lao, Y., Wu, H., Zhao, C., Wu, Q., Qiao, F., Fan, H."Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma". Biomedical Reports 1, no. 5 (2013): 771-775. https://doi.org/10.3892/br.2013.142